TheraRadar
← Back
Data updated: Jun 28, 2026

AARXION ANDA HLDING

Specialty

AARXION ANDA HLDING is a specialty pharmaceutical company focused on Immunology, Gastroenterology.

1981
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

AARXION ANDA HLDING's Key Drugs

AARXION ANDA HLDING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AARXION ANDA HLDING's Recent FDA Approvals

New NDA/BLA approvals for AARXION ANDA HLDING over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AARXION ANDA HLDING's Therapeutic Areas

AARXION ANDA HLDING's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 67%
2 drugs
Gastroenterology 33%
1 drugs

AARXION ANDA HLDING's Top Competitors

AARXION ANDA HLDING's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

AARXION ANDA HLDING Pipeline Snapshot

Active clinical trials for AARXION ANDA HLDING across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling